Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications

References

• PAHO. OMS afirma que COVID-19 é agora caracterizada como pandemia [WHO characterizes COVID-19 as a pandemic] 2020 [cited 2020 Dec 04]. Available from: https://www.paho.org/bra/index.php?option=com_content&view=article&id=6120:oms-afirma-que-covid-19-e-agora-caracterizada-como-pandemia&Itemid=812
   Google Scholar
• WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it: World Health Organization; 2020 [cited 2021 Mar 1st]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
   Google Scholar
• WHO. Operational considerations forcase management of COVID-19 in health facility and community. Technical Documents. 2020 [cited 2021 Mar 1st]:[https://apps.who.int/iris/bitstream/handle/10665/331492/WHO-2019-nCoV-HCF_operations-2020.1-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020 04;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020 Sep;508:254–266.
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus: WHO - World Health Organization; 2020 [cited 2021 Feb 18]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
   Google Scholar
• WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations: World Health Organization; 2020 [cited 2021 Mar 1st]. Available from: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations
   Google Scholar
• Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020 Aug;32(8):1599–1608.
   PubMed Web of Science ®Google Scholar
• Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020 May;141(20):1648–1655.
   PubMed Web of Science ®Google Scholar
• CDC. Older adults and COVID-19: CDC; 2020 [cited 2020 Dec 04]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html
   Google Scholar
• Ogunleye OO, Basu D, Mueller D, et al. Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future. Front Pharmacol. 2020;11:1205.
   PubMed Web of Science ®Google Scholar
• WHO. Brazil: WHO coronavirus disease (COVID-19) dashboard | WJO coronavirus disease (COVID-19) dashboard: WHO - World Health Organization; 2020 [cited 2021 Jan 27]. Available from: https://covid19.who.int/region/amro/country/br
   Google Scholar
• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 05;20(5):533–534.
   PubMed Web of Science ®Google Scholar
• Sefah IA, Ogunleye OO, Essah DO, et al. Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. Front Pharmacol. 2020;11:588106.
   PubMed Web of Science ®Google Scholar
• Godman B, Haque M, Islam S, et al. Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future. Front Public Health. 2020;8:585832.
   PubMed Web of Science ®Google Scholar
• Haque M, Kumar S, Charan J, et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: findings and implications. Front Pharmacol. 2020;11:582154.
   PubMed Web of Science ®Google Scholar
• Brasil. Coronavírus brasil: ministério da saúde; 2020 [cited 2021 Jan 1]. Available from: https://covid.saude.gov.br
   Google Scholar
• Brasil. Ministério da saúde. boletim epidemiológico especial – doença pelo coronavírus COVID-19: ministério da saúde; 2020 [cited 2021 Feb 18]. Available from: https://www.gov.br/saude/pt-br/media/pdf/2020/novembro/13/boletim_epidemiologico_covid_38_final_compressed.pdf
   Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12; 383(27): 2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02; 384(5): 403–416.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb;397(10275):671–681.
   Web of Science ®Google Scholar
• FDA. FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine: FDA; 2020 [cited 2021 February 17]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid
   Google Scholar
• EMA. Treatments and vaccines for COVID-19: authorised medicines EMA. 2021 [cited 2021 Feb 17]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-authorised-medicines#covid-19-vaccines-section
   Google Scholar
• ANVISA. Autorização de Uso Emergencial de Vacinas contra a COVID-19 [Emergency use authorizations of COVID-19 vaccines]: gerência-geral de medicamentos e produtos biológicos; 2021 [cited 2021 Feb 17]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/confira-materiais-da-reuniao-extraordinaria-da-dicol/1-apresentacao-ggmed-coronavac.pdf
   Google Scholar
• Agência europeia recomenda aprovação da vacina de Oxford [Internet]. Agência brasil, EBC - empresa brasileira de comunicação; 2021 [cited 2021 Feb 19]. Available from: https://agenciabrasil.ebc.com.br/internacional/noticia/2021-01/agencia-europeia-recomenda-aprovacao-da-vacina-de-oxford
   Google Scholar
• EMA. EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU. 2021 [cited 2021 Apr 22]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu
   Google Scholar
• Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus (COVID-19) vaccinations: our world in data; 2021 [cited 2021 Mar 1st]. Available from: https://ourworldindata.org/covid-vaccinations
   Google Scholar
• Manavis S Why has the Covid-19 vaccine had such high uptake in the UK?: newStatesman; 2021. Available from: https://www.newstatesman.com/science-tech/coronavirus/2021/04/why-has-covid-19-vaccine-had-such-high-uptake-uk
   Google Scholar
• Brasil. Anvisa aprova uso emergencial da vacina da Janssen [ANVISA approves emergency use of Janssen COVID-19 vaccine] Brasília: ministério da Saúde; 2021 [cited 2021 Apr 16]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-aprova-uso-emergencial-da-vacina-da-janssen
   Google Scholar
• Gomes PH, Falcão M Anvisa pede a ministro suspensão do prazo para decidir sobre importação da vacina Sputnik V [Anvisa asks to ministry to suspend deadline to decide about Sputnik V importation] Brasília: G1; 2021 [cited 2021 Apr 22]. Available from: https://g1.globo.com/bemestar/vacina/noticia/2021/04/20/anvisa-pede-a-ministro-suspensao-do-prazo-para-decidir-sobre-importacao-da-vacina-sputnik-v.ghtml
   Google Scholar
• Ferrari M Anvisa recebe pedido de registro definitivo de vacina da Pfizer contra Covid-19 [Pfizer applies to receive definitive use authorization for its COVID-19 vaccine]: CNN Brasil; 2021 [cited 2021 Feb 19]. Available from: https://www.cnnbrasil.com.br/saude/2021/02/06/anvisa-recebe-pedido-de-registro-definitivo-de-vacina-da-pfizer-contra-covid-19
   Google Scholar
• Cruz EP Taxa de eficácia geral da Coronavac é de 50,38% [Global efficacy of Coronavac is 50.38%] Brazil: Agência Brasil; 2021 [cited 2021 Feb 18]. Available from: https://agenciabrasil.ebc.com.br/saude/noticia/2021-01/taxa-de-eficacia-geral-da-coronavac-e-de-5038
   Google Scholar
• Scliar M. Programa Nacional de Imunizações Brazil: ministério da Saúde; 2003 [cited 2021 Feb 18]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/livro_30_anos_pni.pdf
   Google Scholar
• Domingues CMAS, Maranhão AGK, Teixeira AM, et al. The brazilian national immunization program: 46 years of achievements and challenges. Cad Saude Publica. 2020;36(2):e00222919.
   Google Scholar
• CONASEMS. Confira as orientações do Ministério da Saúde sobre vacinação contra a Covid-19 [Check the orientations of Health Ministry about COVID-19 immunization] Brazil: CONASEMS; 2021 [cited 2021 Jan 26]. Available from: https://www.conasems.org.br/confira-as-orientacoes-do-ministerio-da-saude-sobre-vacinacao-contra-a-covid-19/
   Google Scholar
• Brasil. Plano preliminar de vacinação contra a COVID-19 prevê quatro fases [Vaccination schedule organized in for phases]: ministério da Saúde; 2021 [cited 2021 Jan 24]. Available from: https://www.gov.br/saude/pt-br/assuntos/noticias/vacinacao-contra-a-covid-19-sera-feita-em-quatro-fases
   Google Scholar
• Brasil. Pazuello apresenta cronograma para entregar 230,7 milhões de doses de vacinas contra a Covid-19 até julho [Pazuello presents schedule to deliver 230 million doses of vaccine until july] Brazil: ministério da Saúde; 2021 [cited 2021 Feb 18]. Available from: https://www.gov.br/saude/pt-br/assuntos/noticias/pazuello-apresenta-cronograma-para-entregar-230-7-milhoes-de-doses-de-vacinas-contra-a-covid-19-ate-julho
   Google Scholar
• CNN. Ministério da Saúde negocia 70 milhões de doses de vacina da Pfizer [Health Minister to buy 70 million of COVID-19 vaccine doses from Pfizer] Brazil: CNN Brasil; 2020 [cited 2021 Feb 17]. Available from: https://saude.estadao.com.br/noticias/geral,ministerio-da-saude-e-pfizer-avancam-em-compra-de-70-milhoes-de-doses,70003543591
   Google Scholar
• Leal A Saúde assina intenção de compra de vacinas da Pfizer e da Janssen Brasília: EBC - Agência Brasil; 2021 [cited 2021 Mar 4]. Available from: https://agenciabrasil.ebc.com.br/saude/noticia/2021-03/saude-assina-intencao-de-compra-de-vacinas-da-pfizer-e-da-janssen
   Google Scholar
• Simões E, Boadle A Private Brazilian clinics to buy COVID-19 vaccine from India’s Bharat: reuters; 2021 [cited 2021 Mar 4]. Available from: https://www.reuters.com/article/health-coronavirus-brazil-india-idUSL1N2JF0U8
   Google Scholar
• Piovesan E, Brandão F Câmara aprova projeto que autoriza estados, municípios e setor privado a comprar vacinas [Chamber approves law project that allows states, cities and private market to buy vaccines] Brasília: câmara dos Deputados; 2021 [cited 2021 Mar 26]. Available from: https://www.camara.leg.br/noticias/731990-camara-aprova-projeto-que-autoriza-estados-municipios-e-setor-privado-a-comprar-vacinas/
   Google Scholar
• Brasil. Lei 14.125 de 10/03/2021 [Law number 14,125, 03/10/2021] Brasília: governo Federal; 2021 [cited 2021 Mar 26]. Available from: https://legis.senado.leg.br/norma/33304607.
   Google Scholar
• ANVISA. Câmara de Regulação do Mercado de Medicamentos (CMED). 2021 [cited 2021 Feb 18]. Available from: http://portal.anvisa.gov.br/cmed
   Google Scholar
• ANVISA. Registro de novos medicamentos: saiba o que é preciso: ANVISA; 2018 [cited 2021 Feb 19]. Available from: http://antigo.anvisa.gov.br/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=5062720&_101_type=content&_101_groupId=219201&_101_urlTitle=registro-de-novos-medicamentos-saiba-o-que-e-preciso&inheritRedirect=true
   Google Scholar
• ANVISA. Resolução nº 2, de 5 de março de 2004 [Resolution number 2, March 5, 2004]: ANVISA - Agência Nacional de Vigilância Sanitária; 2004 [cited 2021 Feb 18]. Available from: http://antigo.anvisa.gov.br/resolucao-n-2-de-5-de-marco-de-2004
   Google Scholar
• Machado CV, LDd L, Baptista T. Políticas de saúde no Brasil em tempos contraditórios: caminhos e tropeços na construção de um sistema universal [Health policies in Brazil during contraditory age: paths and obstacles in building a universal system]. Cad Saúde Pública. 2017;33.
   Google Scholar
• De Oliveira GL, Guerra Júnior AA, Godman B, et al. Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):109–119.
   PubMed Web of Science ®Google Scholar
• Llp DL, Guerra Júnior AA, Santos M, et al. The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil. Pharmacoeconomics. 2018 02; 36(2): 161–173.
   PubMed Web of Science ®Google Scholar
• IBGE. Estimativas da População Residente no Brasil e Unidades da Federação com Data de Referência em 1 º de julho de 2020 [Estimatives of Brazilian population as of 1st July] 2020 [cited 2021 Feb 03]. Available from: https://ftp.ibge.gov.br/Estimativas_de_Populacao/Estimativas_2020/POP2020_20201030.pdf
   Google Scholar
• Brasil. Ministério da Saúde. Avaliação de Tecnologias em Saúde [Health Technologies Assessment]. In: Saúde M, editor. Brasília. 2009. p. 112.
   Google Scholar
• Beshears J, Choi JJ, Laibson D, et al. How are preferences revealed? J Public Econ. 2008 August 01;92(8):1787–1794.
   PubMed Web of Science ®Google Scholar
• Kimenju SC, Morawetz UB, De Groote H Comparing contingent valuation method, choice experiments and experimental auctions in soliciting consumer preference for maize in Western Kenya: preliminary results 2005 [cited 2021 Apr 16]:[https://www.researchgate.net/publication/254549821_Comparing_Contingent_Valuation_Method_Choice_Experiments_and_Experimental_Auctions_in_soliciting_Consumer_preference_for_maize_in_Western_Kenya_Preliminary_results
   Google Scholar
• Mould Quevedo JF, Contreras Hernández I, Garduño Espinosa J, et al. El concepto de willingness-to-pay en tela de juicio. Revista de Saúde Pública. 2009;43(2):352–358.
   PubMedGoogle Scholar
• Muniz Júnior RL, Godói IP, Reis EA, et al. Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):473–482.
   PubMed Web of Science ®Google Scholar
• Sarmento TTR, Godói IP, Reis EA, et al. Consumer willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications. Expert Rev Pharmacoecon Outcomes Res, 2019 Dec: 1–8. DOI: https://doi.org/10.1080/14737167.2020.1703181.
   PubMedGoogle Scholar
• Haab T, Ke M. Valuing environmental and natural resources: the econometrics of non-market valuation. Cheltenham, UK: Edward Elgar Pub; 2003.
   Google Scholar
• Athie TS, Nascimento GC, JMLd C, et al. Willingness to pay for a hypothetical chagas disease vaccine in Northern Brazil: a cross-sectional study and the implications. J Comp Eff Res. 2021;10(8):659–672.
   PubMed Web of Science ®Google Scholar
• García LY, Cerda AA. Contingent assessment of the COVID-19 vaccine. Vaccine. 2020 07;38(34):5424–5429.
   PubMed Web of Science ®Google Scholar
• Dong D, Xu RH, Wong EL, et al. Public preference for COVID-19 vaccines in China: a discrete choice experiment. Health Expect. 2020 12; 23(6): 1543–1578.
   PubMed Web of Science ®Google Scholar
• Harapan H, Wagner AL, Yufika A, et al. Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia. Hum Vaccin Immunother. 2020 12; 16(12): 3074–3080.
   PubMed Web of Science ®Google Scholar
• IBGE. IBGE divulga o rendimento domiciliar per capita [IBGE publishes domestic per capita earnings] Brazil 2020 [cited 2021 Jan 27]. Available from: https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/26956-ibge-divulga-o-rendimento-domiciliar-per-capita-2019
   Google Scholar
• Godói IP, Santos AS, Reis EA, et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia. Front Pharmacol. 2017;8:41.
   PubMed Web of Science ®Google Scholar
• ANVISA. Lista de preços de medicamentos [Price list of drugs and health technologies]: CMED - Câmara de Regulação do Mercado de Medicamentos; 2021 [cited 2021 Feb 18].
   Google Scholar
• WHO. Draft landscape of COVID-19 candidate vaccines 2020 [cited 2020 Dec 04]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• Jimoh A, Sofola O, Petu A, et al. Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach. Cost Eff Resour Alloc. 2007 May;5(1):6.
   PubMedGoogle Scholar
• Lumley T. Complex Surveys: a guide to analysis using R. New Jersey, USA: John Wiley & Sons; 2010.
   Google Scholar
• IBGE. Números do Censo 2021 [2021 Census numbers] Brazil 2021 [cited 2021 Jan 27]. Available from: https://censo2021.ibge.gov.br/sobre/numeros-do-censo.html
   Google Scholar
• UOL. Bolsa tem alta de 0,78% e dólar sobe 0,76%, a R$ 5,415, após o Carnaval Brazil: universo Online; 2021 [cited 2021 Feb 18]. Available from: https://economia.uol.com.br/cotacoes/noticias/redacao/2021/02/17/bolsa-dolar-fecha.htm
   Google Scholar
• Galdeano A Covid-19: n ú mero de vacinados no Brasil chega a 2,4 milhões [COVID-19: 2.4 million people vaccinated in Brazil] Brazil: terra; 2021 [cited 2021 Feb 03]. Available from: https://www.terra.com.br/noticias/coronavirus/covid-19-numero-de-vacinados-no-brasil-chega-a-24-milhoes,a64a7b23278fb8b8c67c413e937fa17bowyx0fsd.html
   Google Scholar
• Record. Vacinômetro: 27.106.024 brasileiros tomaram a primeira dose [Vaccinometer: 27,106,024 Brazilian already took the first COVID-19 vaccine dosis]: R7; 2021 [cited 2021 Apr 22]. Available from: https://noticias.r7.com/jr-na-tv/videos/vacinometro-27106024-1280-brasileiros-tomaram-a-primeira-dose-20042021
   Google Scholar
• Kwok KO, Lai F, Wei WI, et al. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020 06; 80(6): e32–e33.
   PubMed Web of Science ®Google Scholar
• Conti P, Caraffa A, Gallenga CE, et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents. 2020 12;35(1(Suppl 1)):1.
   Web of Science ®Google Scholar
• Tang JW, Toovey OTR, Harvey KN, et al. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect. 2021 Jan;82(4):e8–e10.
   PubMed Web of Science ®Google Scholar
• Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, et al. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020;22(1):19.
   PubMed Web of Science ®Google Scholar
• Brockmann D, Helbing D. The hidden geometry of complex, network-driven contagion phenomena. Science. 2013 Dec;342(6164):1337–1342.
   PubMed Web of Science ®Google Scholar
• Lin S, Qiao Y, Huang J, et al. Research on the influence of effective distance between cities on the cross-regional Transmission of COVID-19. medRxiv. 2020;2020(3):27.20044958.
   Google Scholar
• G1. Crise do oxigênio no Amazonas: entenda quanto falta e as ações para repor o insumo [Oxygen crysis in amazonas: understand the situation] Brazil: G1; 2021 [cited 2021 Feb 17]. Available from: https://g1.globo.com/am/amazonas/noticia/2021/01/15/crise-do-oxigenio-no-amazonas-entenda-o-quanto-falta-e-as-acoes-para-repor-o-insumo.ghtml
   Google Scholar
• Thornton J. Covid-19: lack of testing in Brazil is a “major failure,” says MSF. BMJ. 2020 07;370:m2659.
   PubMedGoogle Scholar
• UOL. OMS prevê vacina a US$ 10 a dose. Brasil gastaria R$ 4 bilhões com vulneráveis [WHO estimates vaccine at US$ 10. Immunizatino of vunerable on Brazil would cost 4 billion BRL] 2020 [cited 2021 Feb 18]. Available from: https://noticias.uol.com.br/colunas/jamil-chade/2020/08/24/oms-preve-vacina-a-us-10-a-dose-brasil-gastaria-us-4-bi-com-vulneraveis.htm
   Google Scholar
• ICTQ. Covid19: OMS revela valor estimado da vacina. Brasil já tem preço calculado [COVID-19: WHO reveals estimated price for the vaccine. Brazil already knows how much will pay for them] Brazil: ICTQ; 2020. [cited 2021 Mar 10]. Available from: https://www.ictq.com.br/farmacia-clinica/1951-covid-19-oms-revela-valor-estimado-da-vacina-brasil-ja-tem-preco-calculado
   Google Scholar
• Vasconcelos G Vacina de Oxford custará US$ 3,16 por dose aos cofres públicos, diz Fiocruz Brazil: o Globo; 2020 [cited 2021 Feb 18]. Available from: https://valor.globo.com/brasil/noticia/2020/11/12/vacina-de-oxford-custara-us-316-por-dose-aos-cofres-publicos-diz-fiocruz.ghtml
   Google Scholar
• Garrett JG Vacina do Butantan custa 10 dólares por dose e será paga pelo SUS Brazil: exame; 2020 [cited 2021 Feb 17]. Available from: https://exame.com/brasil/vacina-do-butantan-custa-10-dolares-por-dose-e-sera-paga-pelo-sus/
   Google Scholar
• V S. The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets 2020 [cited 2021 Feb 18]. Available from: https://sputnikvaccine.com/newsroom/pressreleases/the-cost-of-one-dose-will-be-less-than-10-for-international-markets/
   Google Scholar
• Júnior J Projeto autoriza estados, municípios e setor privado a comprarem vacinas contra Covid-19 [Law project allows stated, cities and private market to buy COVID-19 vaccines]: portal da Câmara dos Deputados; 2021 [cited 2021 Mar 26]. Available from: https://www.camara.leg.br/noticias/731344-projeto-autoriza-estados-municipios-e-setor-privado-a-comprarem-vacinas-contra-covid-19
   Google Scholar
• Brasil. 2014. Diretriz de Avaliação Econômica [Economics assessment guideline]. In: Saúde M. editor. 2 ed. Brasília. Ministério da Saúde: 134
   Google Scholar
• Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021 02;9(2):e20–e21.
   PubMed Web of Science ®Google Scholar
• MAKONI, Munyaradzi. South Africa responds to new SARS-CoV-2 variant: land borders have been closed and restrictions continue as a new variant stresses the health system. Lancet. 2021;397:267.
   Web of Science ®Google Scholar
• Murphy CB Consumer Surplus Definition: investopedia; 2021 [cited 2021 Apr]. Available from: https://www.investopedia.com/terms/c/consumer_surplus.asp
   Google Scholar
• Price C. Cost–benefit analysis and willingness to pay for landscape. In: Price C, editor. Landscape Economics. Cham: Springer International Publishing; 2017. p. 133–149.
   Google Scholar
• Danzon PM. Differential pricing of pharmaceuticals: theory, evidence and emerging issues. Pharmaco Economics. 2018 December 01;36(12):1395–1405.
   PubMed Web of Science ®Google Scholar
• Ramsey FP. A Contribution to the Theory of Taxation. Econ J. 1927;37(145):47–61.
   Google Scholar
• BBC. Coronavírus: a eficácia da coronavac e demais vacinas explicada em 4 gráficos Brazil: BBC Brasil; 2021 [cited 2021 Feb 23]. Available from: https://www.bbc.com/portuguese/brasil-55655588
   Google Scholar
• IBGE. Pesquisa Nacional por Amostra de Domicílios (PNAD) 2018. [cited 2021 Mar 08]. Available from: https://www.ibge.gov.br/estatisticas/sociais/populacao/9171-pesquisa-nacional-por-amostra-de-domicilios-continua-mensal.html?=&t=o-que-e
   Google Scholar